ACTA2 and multisystemic smooth muscle dysfunction syndrome: To develop a comprehensive therapy for multisystemic smooth muscle dysfunction syndrome, we used CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 (CRISPR-associated protein 9) adenine base editing to correct the ACTA2 R179H sequence variant.